Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil

Area of Science:

• Urology
• Pharmacology
• Sexual Medicine

Background:

• Phosphodiesterase-5 inhibitors (PDE5Is) are first-line treatments for erectile dysfunction (ED).
• Alprostadil is a second-line treatment option for ED.
• Patients failing monotherapy require alternative treatment strategies.

Purpose of the Study:

• To evaluate the efficacy of combining PDE5Is with alprostadil in patients with ED who have not responded to monotherapy.
• To assess treatment outcomes and side effects of combination therapy.

Main Methods:

• A PubMed search identified nine publications on combination therapy with PDE5Is and alprostadil.
• Alprostadil formulations included intracavernosal, intraurethral, and topical applications.
• Outcomes were measured using International Index of Erectile Function (IIEF) scores.

Main Results:

• Combination therapy with PDE5Is and alprostadil demonstrated improved erectile function compared to monotherapy.
• Significant increases in total IIEF and IIEF erectile function domain scores were observed.
• This benefit was noted in patients with post-prostatectomy ED.
• Adverse effects did not lead to treatment discontinuation.

Conclusions:

• Combination therapy with PDE5Is and alprostadil is a promising option for ED patients with suboptimal responses to monotherapy.
• This approach may enhance erectile function and patient satisfaction.
• Further consideration of this combination therapy is warranted for refractory ED cases.